A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)

OBJECTIVE: The aim of this study was to examine the long‐term efficacy of combination of tamsulosin 0.2 mg + dutasteride 0.5 mg + imidafenacin 0.2 mg (TDI) therapy compared with tamsulosin + dutasteride (TD) therapy for 52 weeks in benign prostatic hyperplasia (BPH) patients with a prostate volume (...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamanishi, Tomonori, Asakura, Hirotaka, Seki, Narihito, Tokunaga, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Asia Pty Ltd 2018
Materias:
Original Articles ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379254/
https://www.ncbi.nlm.nih.gov/pubmed/30358116
http://dx.doi.org/10.1111/luts.12243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379254/
https://www.ncbi.nlm.nih.gov/pubmed/30358116
http://dx.doi.org/10.1111/luts.12243

Ejemplares similares